GSK3B and cancer: The levels of glycogen synthase (GS) phosphorylated at Y641 (p-GSS641) and p-β-cateninS33/37/T41 decreased in cancer cells following treatment with AR-A014418 (Fig. S1A, B), indicating its activity against GSK3β in cancer cells.